---
title: 'Industry Daily Summary: What Happened on November 13, 2026'
headline: Cellectis may cut up to 70% of its workforce in shift to in vivo therapies
description: Takeda began U.S. sales of its narcolepsy drug, Bristol Myers Squibb
  set a unified R&D structure, and European biotechs changed leaders and advanced
  drug plans.
url: https://thebench.bio/news/industry/2026-11-13
topic: industry
date: '2026-11-13'
covers:
- '2026-11-13'
date_published: '2026-11-13T12:04:10Z'
date_modified: '2026-11-14T00:04:41Z'
tags:
- Industry
- Funding
- Research
sources: 5
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on November 13, 2026

**Cellectis may cut up to 70% of its workforce in shift to in vivo therapies**

Takeda began U.S. sales of its narcolepsy drug, Bristol Myers Squibb set a unified R&D structure, and European biotechs changed leaders and advanced drug plans.

## Today in brief

Cellectis may eliminate as many as 160 jobs as it shifts toward in vivo gene editing, a reduction of up to 70% of its workforce. [1] It also stopped enrollment in two cell-therapy programs and expects its funding to last into the second half of 2028. [1]

Takeda has begun U.S. sales of Orzeyful, approved for adults with narcolepsy type 1. [2] Bristol Myers Squibb will put research and development under chief medical officer Cristian Massacesi starting January 1, 2027. Research chief Robert Plenge will leave after an advisory period. [3]

## Cellectis considers workforce cuts of up to 70%

Cellectis said its shift toward in vivo therapies could reduce its global workforce by as much as 70%. [1] The company had 229 full-time employees at the end of 2025, putting the maximum potential reduction at about 160 people. [1]

The changes could affect staff through the rest of 2026 and into 2027, subject to consultation with the French works council and labor-law requirements in France and the United States. [1] Cellectis halted enrollment in its lasme-cel and eti-cel clinical programs, but will continue required follow-up of treated patients. [1]

The company is shifting resources to HEAL-101, an in vivo base-editing candidate for severe hypertriglyceridemia, and HEAL-201, an epigenetic-editing candidate for severe hypercholesterolemia. [1] Cellectis expects initial HEAL-101 clinical data in the second half of 2027 and preliminary HEAL-201 data in the first half of 2028, from planned investigator-initiated trials in China. [1]

Cellectis reported $149 million in cash and specified financial assets as of September 30. It expects that funding to support operations into the second half of 2028. [1]

## Takeda begins U.S. sales of Orzeyful for narcolepsy type 1

Takeda began commercial distribution of Orzeyful, also called oveporexton, for adults with narcolepsy type 1 in the United States. [2] The FDA approved the drug in August 2026. It received Schedule IV controlled-substance classification. [2]

Orzeyful activates orexin receptor 2, a pathway intended to address the orexin deficiency associated with narcolepsy type 1 and promote wakefulness. [2] Accredo Specialty Pharmacy, part of Evernorth Health Services, handles nationwide distribution. Takeda offers eligible adults help starting treatment and navigating coverage. [2]

Common adverse effects reported in clinical evaluations included insomnia, excess saliva, urinary urgency, and frequent urination. [2] Takeda is also developing oral orexin agonists TAK-360 and TAK-495. TAK-360 is in clinical development for idiopathic hypersomnia and narcolepsy types 1 and 2. [2]

## Bristol Myers Squibb combines research and development under Massacesi

Bristol Myers Squibb plans to combine its separate research and development departments into one organization on January 1, 2027, led by chief medical officer Cristian Massacesi. [3]

Robert Plenge will advise the company through March 2027, then leave. The advisory role is intended to support the transition. [3] CEO Christopher Boerner said the unified structure is meant to connect scientific and clinical expertise, speed decisions, and improve portfolio execution. [3]

## European biotech updates include a Gubra CEO change

Gubra replaced CEO Markus Rohrwild, who left on November 10. CFO Kristian Borbos and business development leader Zoë Johnson are serving as co-CEOs while keeping their current roles. [4] The board said the change was needed to implement the company’s strategy, which remains unchanged. [4]

Gubra aims to increase its clinical-stage portfolio from four assets to eight to ten by 2030, launch two or three ventures, and achieve average annual organic growth of 10% in its preclinical research business. [4]

Commit Biologics selected COM002 as its first drug candidate and appointed Anne-Marie Levy Rasmussen as chief operating officer and Benjamin Ole Wolthers as head of clinical development. [4] Commit expects to dose the first participant in a Phase 1 trial in early 2028. [4]

TECregen named Elisabeth Svanberg chief medical officer as it prepares preclinical candidate TEC001 for work supporting an investigational new drug application. [4] TEC001 is initially aimed at immune impairment linked to advanced kidney disease. [4]

SRTD Biotech raised €31.5 million in seed financing and appointed Matthias Alder CEO. The company plans to use the financing to support preclinical programs in cancer, autoimmune disease, and fibrosis. [4] DaltonTx named Melissa Landon chief commercial officer. Trogenix appointed John Young chair and is considering partnerships and future financing as it runs a Phase 1/2 study of TGX-007 in glioblastoma. [4]

## Also worth knowing

- Oura agreed to acquire Counsel Health, whose clinicians will be able to use data from Oura rings. Eli Lilly lists Counsel among providers for patients seeking a GLP-1 prescription, a relationship expected to become more complicated after the deal. [5]

## The day in numbers

- **Up to 70%**: Maximum share of Cellectis's workforce that could be cut, equivalent to about 160 of its 229 employees at the end of 2025. [1]
- **$149 million**: Cellectis's reported cash and specified financial assets as of September 30. The company expects funding to last into the second half of 2028. [1]
- **January 1, 2027**: Date Bristol Myers Squibb plans to combine its research and development departments. [3]

## Also published

- [A Prediction I'd Have Preferred to Have Gotten Wrong](<https://omicsomics.blogspot.com/feeds/7181259847213843449/comments/default>), Omics! Omics!
- [BIO Europe: Financing, AI and geopolitics shape biotech discourse ](<https://www.pharmaceutical-technology.com/features/bio-europe-2026-financing-ai-geopolitics-shape-biotech-discourse/>), Pharmaceutical Technology
- [Bipartisan push possible to curb Trump tariffs](<https://www.medtechdive.com/news/bipartisan-push-possible-to-curb-trump-tariffs/874520/>), MedTech Dive
- [Why the Next Wave of Drug Launches Will Be Won on Market Access](<https://www.pharmaceuticalcommerce.com/view/why-the-next-wave-of-drug-launches-will-be-won-on-market-access>), Pharmaceutical Commerce
- [3 quotes that show why MAHA is cheering Stephen Miller’s ascension](<https://www.pharmavoice.com/news/maha-stephen-miller-rfk-fda-pharma-drug/874546/>), PharmaVoice
- [Rapid DEA review clears way for Takeda's narcolepsy launch](<https://pharmaphorum.com/news/rapid-dea-review-clears-way-takedas-narcolepsy-launch>), pharmaphorum
- [Life sciences real estate: Beyond labs](<https://pharmaphorum.com/rd/life-sciences-real-estate-beyond-labs>), pharmaphorum
- [Envirogen secures place on NHS Scotland reverse osmosis framework](<https://pharmafile.com/news/envirogen-secures-place-on-nhs-scotland-reverse-osmosis-framework/>), Pharmafile
- [BMS parting with Plenge amid R&D reorganization](<https://www.biocentury.com/article/661598/bms-parting-with-plenge-amid-r-d-reorganization?utm_source=bc_rss&utm_medium=rss>), BioCentury
- [From hope to adoption: an industry perspective on the maturation of new approach methodologies](<https://www.nature.com/articles/s41573-026-01583-4>), Nature Reviews Drug Discovery
- [How can gene therapy platforms be scaled up to treat thousands of rare diseases?](<https://www.nature.com/articles/d41573-026-00179-2>), Nature Reviews Drug Discovery
- [BMS shakes up R&D under CMO Cristian Massacesi](<https://pharmaphorum.com/news/bms-shakes-rd-under-cmo-cristian-massacesi>), pharmaphorum
- [STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment](<https://www.statnews.com/2026/11/12/biotech-news-blackstone-backs-pfizer-bet-on-monthly-obesity-treatment/?utm_campaign=rss>), STAT Biotech
- [Bristol Myers research chief to depart in ‘evolution’ of company’s structure](<https://www.biopharmadive.com/news/bristol-myers-robert-plenge-cristian-massacesi-research-transition/874476/>), BioPharma Dive

## Sources

1. [Cellectis could cut 70% of workforce in shift to in vivo therapies](<https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies>), BioSpace, 2026-11-13
2. [Takeda begins US distribution of narcolepsy type 1 drug Orzeyful](<https://www.pharmaceutical-technology.com/news/takeda-us-distribution-orzeyful/>), Pharmaceutical Technology, 2026-11-13
3. [BMS sets unified research and development structure for 2027](<https://www.pharmaceutical-technology.com/news/bms-unified-research-and-development-structure-2027/>), Pharmaceutical Technology, 2026-11-13
4. [Gubra’s board replaces CEO; Commit staffs its first drug program; TECregen names CMO](<https://european-biotechnology.com/latest-news/gubras-board-replaces-ceo-commit-staffs-its-first-drug-program-tecregen-names-cmo/>), European Biotechnology, 2026-11-13
5. [STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say](<https://www.statnews.com/2026/11/13/oura-acquisition-counsel-health-eli-lilly/?utm_campaign=rss>), STAT Biotech, 2026-11-13

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies>
[2]: <https://www.pharmaceutical-technology.com/news/takeda-us-distribution-orzeyful/>
[3]: <https://www.pharmaceutical-technology.com/news/bms-unified-research-and-development-structure-2027/>
[4]: <https://european-biotechnology.com/latest-news/gubras-board-replaces-ceo-commit-staffs-its-first-drug-program-tecregen-names-cmo/>
[5]: <https://www.statnews.com/2026/11/13/oura-acquisition-counsel-health-eli-lilly/?utm_campaign=rss>
